MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412167 | Name: Tetroxoprim

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tetroxoprim is an inhibitor of bacterial dihydrofolate reductase. Tetroxoprim (INN) is a derivative of trimethoprim.

Chemical Structure

Tetroxoprim
CAS#53808-87-0

Theoretical Analysis

MedKoo Cat#: 412167

Name: Tetroxoprim

CAS#: 53808-87-0

Chemical Formula: C16H22N4O4

Exact Mass: 334.1641

Molecular Weight: 334.38

Elemental Analysis: C, 57.47; H, 6.63; N, 16.76; O, 19.14

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Tetroxoprim; BW32 U; BW-32 U; BW 32 U
IUPAC/Chemical Name
2,4-Pyrimidinediamine, 5-((3,5-dimethoxy-4-(2-methoxyethoxy)phenyl)methyl)-
InChi Key
InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20)
InChi Code
InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20)
SMILES Code
NC1=NC=C(CC2=CC(OC)=C(OCCOC)C(OC)=C2)C(N)=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 334.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kaur D, Mathew S, Nair CGS, Begum A, Jainanarayan AK, Sharma M, Brahmachari SK. Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug resistant Mycobacterium tuberculosis. J Transl Med. 2017 Dec 21;15(1):261. doi: 10.1186/s12967-017-1363-9. PMID: 29268770; PMCID: PMC5740895. 2: Caira MR, Bettinetti G, Sorrenti M, Catenacci L. Order-disorder enantiotropy, monotropy, and isostructurality in a tetroxoprim-sulfametrole 1:1 molecular complex: Crystallographic and thermal studies. J Pharm Sci. 2003 Nov;92(11):2164-76. doi: 10.1002/jps.10435. PMID: 14603502. 3: Caira MR, Bettinetti G, Sorrenti M. Structural relationships, thermal properties, and physicochemical characterization of anhydrous and solvated crystalline forms of tetroxoprim. J Pharm Sci. 2002 Feb;91(2):467-81. doi: 10.1002/jps.10034. PMID: 11835206. 4: Gabriëls G, Stockem E, Greven J. Potassium-sparing renal effects of trimethoprim and structural analogues. Nephron. 2000 Sep;86(1):70-8. doi: 10.1159/000045715. PMID: 10971156. 5: Then RL. History and future of antimicrobial diaminopyrimidines. J Chemother. 1993 Dec;5(6):361-8. PMID: 8195827. 6: Walzer PD, Foy J, Steele P, White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436-43. doi: 10.1128/aac.37.7.1436. PMID: 8363372; PMCID: PMC187990. 7: Sheikh Salem M, Alkaysi HN, Gharaibeh AM, Amari FF, Sallam E, Shubair MS. Analysis and bioequivalency study on two tablet formulations of co-trimoxazole. J Clin Pharm Ther. 1993 Apr;18(2):109-14. doi: 10.1111/j.1365-2710.1993.tb00576.x. PMID: 8458878. 8: Alkaysi HN, Salem MA, Gharaibeh AM, Gharaibeh KI, Badwan AA. Bioequivalency studies on tablet formulation of tetroxoprim and sulphadiazine. J Clin Pharm Ther. 1992 Apr;17(2):97-9. doi: 10.1111/j.1365-2710.1992.tb01274.x. PMID: 1583085. 9: Nelis HJ, Léger F, Sorgeloos P, De leenheer AP. Liquid chromatographic determination of efficacy of incorporation of trimethoprim and sulfamethoxazole in brine shrimp (Artemia spp.) used for prophylactic chemotherapy of fish. Antimicrob Agents Chemother. 1991 Dec;35(12):2486-9. doi: 10.1128/aac.35.12.2486. PMID: 1810182; PMCID: PMC245417. 10: Alkaysi HN, Salem MS, Badwan AA. High performance liquid chromatographic analysis of tetroxoprim and sulphadiazine in serum and urine. Biomed Chromatogr. 1991 Nov;5(6):265-8. doi: 10.1002/bmc.1130050608. PMID: 1662101. 11: Selassie CD, Li RL, Poe M, Hansch C. On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted- benzyl)pyrimidines with dihydrofolate reductase. J Med Chem. 1991 Jan;34(1):46-54. doi: 10.1021/jm00105a008. PMID: 1899453. 12: Scordamaglia A, Bagnasco M, Borella F, Colombo F, Ciprandi G, Canonica GW. Effects of tetroxoprim and sulfadiazine on T lymphocyte proliferation and gamma- interferon production. J Chemother. 1989 Jun;1(3):207-10. doi: 10.1080/1120009x.1989.11738892. PMID: 2507751. 13: Springolo V, Coppi G. HPLC determination of tetroxoprim and sulphadiazine in pharmaceutical dosage forms and in biological fluids. J Pharm Biomed Anal. 1989;7(1):57-65. doi: 10.1016/0731-7085(89)80067-6. PMID: 2488608. 14: Gambaro MG, Genoni P, Berra D. L'associazione sulfadiazina-tetroxoprim (co- tetroxazina) nel trattamento delle riacutizzazioni delle broncopatie croniche [A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis]. Minerva Med. 1988 Jul;79(7):563-8. Italian. PMID: 3043259. 15: Araujo FG, Guptill DR, Remington JS. In vivo activity of piritrexim [corrected] against Toxoplasma gondii. J Infect Dis. 1987 Nov;156(5):828-30. doi: 10.1093/infdis/156.5.828. Erratum in: J Infect Dis 1988 Mar;157(3):614. PMID: 3484324. 16: Westenfelder M, Vahlensieck W, Reinhartz U. Patient compliance and efficacy of low-dose, long-term prophylaxis in patients with recurrent urinary tract infection. Chemioterapia. 1987 Jun;6(2 Suppl):530-2. PMID: 3509492. 17: Donovski L, Tsvetkov D. Lechenie na khronichniia bakterialen prostatit s preparata tibiroks [Treatment of chronic bacterial prostatitis with the preparation tibirox]. Khirurgiia (Sofiia). 1987;40(6):17-22. Bulgarian. PMID: 3437708. 18: Ferrara A, Behar V, Coppi G. Co-tetroxazina: rassegna e contributi personali [Co-tetroxazine: review and personal contributions]. G Ital Chemioter. 1986 Jan- Apr;33(1):27-44. Italian. PMID: 3817375. 19: Sánchez Sevillano A, Cepeda Rodrigo JM, Pérez-Mateo M. La tetroxoprima- sulfadiacina en el tratamiento de la fiebre tifoidea [Tetroxoprim-sulphadiazine in the treatment of typhoid fever]. Med Clin (Barc). 1985 Nov 9;85(15):642. Spanish. PMID: 4079552. 20: Hussain Z, Carlson ML, Craig ID, Lannigan R. Efficacy of tetroxoprim/sulphadiazine in the treatment of Pneumocystis carinii pneumonitis in rats. J Antimicrob Chemother. 1985 May;15(5):575-8. doi: 10.1093/jac/15.5.575. PMID: 3874200.